Global Blood Therapeutics, Inc.
GBT · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.31 | 0.93 | -0.51 | -0.51 |
| FCF Yield | -14.12% | -8.31% | -4.27% | -6.68% |
| EV / EBITDA | -6.52 | -10.20 | -17.17 | -10.76 |
| Quality | ||||
| ROIC | -33.56% | -37.42% | -38.72% | -31.30% |
| Gross Margin | 98.30% | 98.40% | 97.72% | 0.00% |
| Cash Conversion Ratio | 0.85 | 0.86 | 0.73 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | 352.07% | – | – | – |
| Free Cash Flow Growth | -17.87% | -11.49% | -41.14% | -45.85% |
| Safety | ||||
| Net Debt / EBITDA | 0.09 | 1.50 | 0.88 | 1.62 |
| Interest Coverage | -18.57 | -24.79 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.06 | 0.05 | 0.04 | 0.00 |
| Cash Conversion Cycle | 4,798.65 | 3,937.76 | -70,596.74 | 0.00 |